After going public in July 2021, biotech startup Rallybio is raising an additional $50 million through an offering of 5 million shares.
The company was founded by three former Alexion Pharmaceutical executives at UConn’s Technology Incubation Program facility in Farmington. It moved to New Haven in 2020.
The company has begun Phase 1 clinical trials on a drug, RLYB212, that aims to prevent fetal and neonatal alloimmune thrombocytopeniaa, a blood disorder that affects pregnant women.